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Uterine leiomyomas are common benign tumors of the myometrium. We performed a meta-
analysis of two genome-wide association studies of leiomyoma in European women (16,595
cases and 523,330 controls), uncovering 21 variants at 16 loci that associate with the disease.
Five variants were previously reported to confer risk of various malignant or benign tumors
(rs78378222 in TP53, rs10069690 in TERT, rs1800057 and rs1801516 in ATM, and
rs7907606 at OBFC1) and four signals are located at established risk loci for hormone-related
traits (endometriosis and breast cancer) at 1q36.12 (CDC42/WNT4), 2p25.1 (GREB1), 20p12.3
(MCM8), and 6q26.2 (SYNE1/ESR1). Polygenic score for leiomyoma, computed using UKB
data, is signiﬁcantly correlated with risk of cancer in the Icelandic population. Functional
annotation suggests that the non-coding risk variants affect multiple genes, including ESR1.
Our results provide insights into the genetic background of leiomyoma that are shared by
other benign and malignant tumors and highlight the role of hormones in leiomyoma growth.
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Uterine leiomyomas, sometimes referred to as ﬁbroids, arebenign tumors that arise in the smooth muscle cells of theuterine wall1. Leiomyomas represent the most common
pelvic tumors in women with prevalence by the age 50, above
80% for African–American women, and nearly 70% for Cauca-
sian women2. Although leiomyomas are non-malignant and in
majority of cases not symptomatic, about 20–25% of cases cause
problems that warrant treatment. These symptoms include
dysmenorrhea, pelvic pain, abnormal bleeding, infertility, and
complications during pregnancy3. Leiomyomas are estrogen
responsive and many of the non-surgical therapeutic options
involve some form of hormonal manipulation; however, in many
cases, the tumors recur when therapy is discontinued1. Leio-
myomas are the most common indication for hysterectomy and
the second most common cause of surgical intervention for
women after cesarean section, with over 600,000 hysterectomies
performed per year in the USA4.
The biological mechanisms leading to the development of
uterine leiomyomas are not well understood. Risk factors include
age, obesity, increased levels of estrogens, hypertension, parity,
and race, with prevalence in African–American women being
considerably higher than that in European–American women2.
Genetic factors are also implicated in leiomyoma formation: First-
degree relatives of affected women have a 2.5-fold greater risk of
developing the condition than the population average5 and the
concordance among monozygotic twins is almost twice that of
dizygotic twins6. A genome-wide association study (GWAS) in
Japanese women found variants at three loci that associate with
uterine leiomyoma, at 22q13.1 (TNRC6B), 11p15.5 (BET1L), and
10q24.33 (OBFC1)7. The associations between the disease and the
ﬁrst two loci have been conﬁrmed in European women8. Finally, a
GWAS of leiomyoma risk among African–American women
yielded a locus on 22q13.1 (CYTH4)9.
To gain insights into the genetic causes of uterine leiomyomas,
we performed a meta-analysis of leiomyoma in Europeans, using
GWAS data on 16,595 cases and 523,330 controls from Iceland
and the UK, identifying 21 variants at 16 loci that associate with
the disease.
Results
Association analysis. We combined the results of two GWAS‘ of
uterine leiomyoma, one from Iceland and the other from the UK
Biobank (UKB), using a total of 16,595 cases and 523,330 controls
of conﬁrmed Europen descent. The Icelandic GWAS consists of
6728 hospital-based, histologically conﬁrmed leiomyoma cases
and 124,542 controls, whereas the UKB leiomyoma dataset is
based on 9867 hospital-based cases and 398,788 controls. A
Manhattan plot of the meta-analysis results is shown in Fig. 1. As
the probability of a variant impacting a phenotype differs between
the functional annotation classes10, we applied genome-wide
signiﬁcance thresholds using a weighted Bonferroni procedure
that takes this prior probability into account and corrects for all
43,421,991 variants tested (Supplementary Data 1, Methods).
Using this scheme, a total of 412 variants at 16 loci reach the
threshold of genome-wide signiﬁcance (Supplementary Data 2).
We applied conditional analysis to search for distinct signals at
each locus and ﬁnd additional variants at ﬁve loci that associate
with leiomyoma independent of the main signal (with Pcond <
10−6); three of the secondary signals reach genome-wide
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Fig. 1 Manhattan plot of the association results of meta-analysis of leiomyoma of the uterus. The Manhattan plot shows variants with P-value < 1.0 × 10−3
in a meta-analysis of GWAS data from 20,621 leiomyoma patients and 280,541 controls of European ancestry. Shown are negative log10-transformed P
values (y-axis) over 22 autosomes (x-axis). Red font color indicates leiomyoma loci previously reported in the Japanese population
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signiﬁcance. The 19 genome-wide signiﬁcant markers and two
signiﬁcant secondary signals are listed in Table 1 and Supple-
mentary Data 3, locus plots for all the markers are presented
in Supplementary Fig. 1, and all association signals with
P value < 5.0 × 10−8 are listed in Supplementary Data 4. We also
tested 21 markers for association with 20 different tumor types
using information on 42,331 cancer cases from the Icelandic
Cancer Registry and several phenotypes that are strongly affected
by estrogen exposure, i.e., endometriosis (1,857 cases), bone
mineral density (BMD, 28,900 individuals), and age at meno-
pause (10,216 individuals) (Supplementary Data 5 and 6).
Variants at 16 loci associate with leiomyoma. Examination of
the meta-analysis results suggests that at least two genetic
pathways play a role in the development of leiomyomas; one
linked to tumorigenesis and the other linked to hormone-related
traits (Table 1, Supplementary Data 3). The most signiﬁcant
association with leiomyoma is with a low-frequency 3’UTR var-
iant in TP53, rs7837822_G (P= 4.03 × 10−37, meta-analysis of
logistic regression, OR= 1.74). The same allele of this variant was
previously reported to associate with increased risk of several
malignant and benign tumor types, including basal cell skin
cancer, glioma, prostate cancer, neuroblastoma, and colorectal
adenoma11–13. Four additional leiomyoma variants in our meta-
analysis, one at the TERT locus, two in ATM, and one at the
OBFC1 locus, have previously been associated with cancer risk.
At the TERT locus, rs10069690_T was previously reported to
increase the risk of thyroid cancer14, estrogen and progesterone
receptor-negative breast cancer15,16, CLL17, and glioma18 and
Table 1 Association results for lead variants at loci reaching genome-wide signiﬁcance in meta-analysis of leiomyoma
Marker Name
Pos hg381
coding effect EAF EA/
OA
Gene OR2meta (95%
CI)
Pmeta Phenotypes reported at locus3
rs10917151
chr1:22096228
downstream 0.201 A/G CDC42/
WNT4
1.12 (1.09, 1.16) 5.1E-14 Endometriosis, BMD, OvCa
rs148143917
chr2:11524625
upstream 0.019 C/A GREB1 0.74 (0.67,
0.82)
8.1E-10 Endometriosis, BrCa
rs10929757
chr2:11562535
missense Asn77Thr 0.410 A/C GREB1 0.92 (0.90,
0.94)
8.1E-12 Endometriosis, BrCa
rs479404
chr3:27321573
intron 0.322 C/T NEK10 1.09 (1.06, 1.12) 8.9E-11 BrCa
rs765333492
chr4:53021103
intron 0.003 C/T SCFD2 2.76 (2.11, 3.6) 2.3E-13
rs2202282
chr4:69768723
intergenic 0.485 T/C SULT1E1 1.09 (1.07-1.12) 6.5E-13
rs10069690
chr5:1279675
intron 0.259 T/C TERT 1.12 (1.1, 1.15) 3.6E-18 ThCa, BrCa, CLL, TeCa, PrCa,
UBC, PaCa, glioma
rs58415480
chr6:152241136
intron 0.142 G/C SYNE1/
ESR1
1.18 (1.14, 1.22) 9.0E-24 Endometriosis
rs73639400
chr9:683423
intron 0.142 C/T KANK1 1.12 (1.09-1.16) 7.9E-12
rs7030354
chr9:804231
intergenic 0.404 T/C DMRT1 1.11 (1.08, 1.14) 2.0E-17
rs7907606
chr10:103920874
upstream 0.155 G/T OBFC1 1.1 (1.07, 1.14) 3.1E-09 LM (Japan), BCC, multiple cancers, telomere
length
rs11246001
chr11:210899
upstream 0.044 T/C BET1L 0.82 (0.78-
0.87)
5.2E-12 LM (Japan)
rs507139
chr11:225196
intron 0.082 A/G SIRT3 0.83 (0.80,
0.87)
1.4E-16 LM (Japan)
rs11031731
chr11:32343884
intergenic 0.158 A/G WT1 1.14 (1.10-1.17) 5.4E-16
rs1800057
chr11:108272729
missense
Pro1054Arg
0.020 G/C ATM 1.28 (1.19, 1.38) 3.1E-11 CLL, PrCa, RCC
rs18015164
chr11:108304735
missense
Asp1853Asn
0.152 A/G ATM 0.91 (0.88,
0.94)
7.4E-08 CMM, response to radio/chemotherapy
rs117245733
chr13:40149807
intergenic 0.020 A/G LINC0 1.32 (1.21, 1.44) 2.2E-10
rs79864074
chr13:40605661
intron 0.305 G/A FOXO1 1.07 1.04, 1.10() 7.0E-08
rs78378222
chr17:7668434
3’UTR 0.018 G/T TP53 1.74 (1.6, 1.89) 4.0E-37 BCC, PrCa, glioma, CR adenoma, NB
rs16991615
chr20:5967581
missense Glu341Lys 0.081 A/G MCM8 1.16 (1.11, 1.21) 3.6E-10 Age at menopause, BrCa
rs12484951
chr22:40307071
intron 0.252 G/T TNRC6B 1.11 (1.08, 1.14) 3.2E-13 LM (Japan)
See Supplementary Data 6 for results in the Icelandic and UKB datasets and references for the reported signals referred to in the table
1Marker positions are according to GRCh38/hg38,
2Odds-ratios correspond to effect alleles,
3Phenotypes relating to tumorigenesis or hormone-related traits previously reported at the locus,
4Secondary signals reaching conditional P value < 10-6 (approximately 30.000 variants tested)
Abbreviations: EAF, effect allele frequency; EA, effect allele; OA, other allele, PMeta, P-value for ﬁxed effects meta-analysis; ORMeta, Odds ratio; BMD, bone mineral density; OvCa, ovarian cancer; BrCa,
breast cancer; TeCa, testicular cancer; LM, leiomyoma, PrCa, prostate cancer; UBC, urinary bladder cancer; ThCa, thyroid cancer; PaCa, pancreatic cancer; BCC, basal cell carcinoma, CLL, chronic
lymphocytic leukemia: RCC, renal cell carcinoma; CMM, cutaneous malignant melanoma; CR adenoma, colorectal adenoma; NB, neuroblastoma
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decrease the risk of testicular, prostate, bladder, and pancreatic
cancers18. Two uncorrelated (r2= 0.007) missense variants
in the ATM gene, rs1801516 (Asp1853Asn) and rs1800057
(Pro1054Arg), independently associate with leiomyoma.
rs1801516_A was previously reported to associate with decreased
melanoma risk19 and response to chemotherapy and radio-
therapy20,21. This variant shows signiﬁcant association with
increased risk of squamous cell skin cancer in Iceland (P= 4.35 ×
10−5, logistic regression, OR= 1.21) after correction for the
number of phenotypes tested (P < 0.05/29= 1.72 × 10−3), the
direction of effect being opposite to the reported melanoma effect
(Supplementary Data 6). The other leiomyoma missense variant
in ATM, rs1800057_G, has been linked to increased risk of
chronic lymphocytic leukemia22, prostate cancer23, and renal cell
carcinoma24. Finally, at the OBFC1 locus, the strongest leio-
myoma risk variant, rs7907606_G, has previously been associated
with the risk of basal cell carcinoma25 and is strongly correlated
with variants that have been reported for risk of melanoma26,
adenocarcinoma of the lung27, thyroid cancer14, renal cell carci-
noma24, serous ovarian cancer28, glioma29, and CLL30, as well as
to telomere length31.
Several of the leiomyoma variants and loci emerging from our
meta-analysis have been linked to hormone-related traits.
Variants at the CDC4/WNT4 locus have been associated with
endometriosis, BMD, bone size, and ovarian cancer32–35. The
leiomyoma variant rs10917151 at this locus is correlated with the
strongest reported endometriosis variant (r2= 1), as well as the
ovarian cancer variant (r2= 0.97), and one of the BMD variants
(r2= 0.81) (Table 1, Supplementary Data 3). The missense
variant in MCM8, rs16991615_A, that associates with increased
risk of leiomyoma in our study, also associates with delayed onset
of menopause36, breast cancer37, and with increased BMD in
Iceland (Supplementary Data 6). At the SYNE1/ESR1 locus, the
strongest leiomyoma variant, rs58415480, is correlated with a
reported endometriosis variant rs71575922 (r2= 0.94)32. Notably,
the leiomyoma variant is not correlated to any of the six
independent breast cancer signals reported in European popula-
tions at this locus, represented by the variants rs9397435/
rs9397437, rs3757322, rs851984, rs9918437, rs78796841, and
rs274765237–39 (all r2 < 0.03 in CEU). Two variants at the GREB1
locus, the missense variant rs10929757 (Asn77Thr) and
rs148143917 (upstream variant), associate with leiomyoma. Two
association signals for endometriosis have been reported at this
locus32, but neither are strongly correlated with the leiomyoma
variants (Table 1). The leiomyoma variant rs10929757
(Asn77Thr) associates with endometriosis, whereas only one of
the endometriosis variants, rs77294520, associates with leio-
myoma in the Icelandic data (Supplementary Data 6 and 7). Two
additional variants have potential links to hormone metabolism.
First, rs2202282 at 4q13.3 is located in a cluster of sulfotransferase
genes, including SULT1E1, which catalyzes the sulfation of
estrogens40. Second, the low-frequency variant rs765333492
(SCFD2, MAF= 0.3%) found only in the Icelandic dataset also
shows suggestive association with endometriosis in Iceland (P=
0.018, logistic regression, OR= 1.92) (Supplementary Data 6).
Variants at three loci previously reported for uterine ﬁbroids in
Japanese women7, 22q13.1 (TNRC6B), 11p15.5 (BET1L), and
10q24.33 (OBFC1), reached genome-wide signiﬁcance in our
meta-analysis. Our top TNCRB6 variant is strongly correlated
with the variant reported in Japanese women (r2= 0.97). At the
BET1L locus, we found two distinct signals, one of which is fully
correlated with the reported BET1L variant in Japanese women
(Table 1, Supplementary Data 3). At the OBFC1 locus, the
previously discussed cancer-associated variant rs7907606 is not
correlated with the Japanese leiomyoma variant reported
(rs7913069, P= 0.98, meta-analysis of logistic regression, OR=
1.0, r2= 0.001 in Europeans and 0.014 in Japanese). To further
analyze the Japanese signal in our data, we tested 278 variants
that correlate with rs7913069 (with r2 > 0.1) in the Japanese
population for association with leiomyoma in our dataset
(Supplementary Data 8). The lowest P-value observed is
0.00015 for rs78381949, a variant that correlates with r2= 0.23
with rs7913069 in East-Asians, but has very little correlation with
rs7907606 (r2= 0.04) in Caucasians. It is thus unlikely that
rs7907606 and rs7913069 are tagging the same association signal.
Finally, the variant at the CYTH4 locus identiﬁed in
African–American women9, rs739187, does not associate with
leiomyoma in our data (P= 0.51, meta-analysis of logistic
regression, OR= 1.01). rs739187 is about 3Mb away from the
leiomyoma variant rs12484951 (TNRC6B) and the 2 variants are
not correlated either in Europeans (r2= 0.0064) or
African–Americans (r2= 0.017).
Overlap of leiomyoma, endometriosis, and endometrial cancer.
Although a large fraction of hysterectomies are due to leio-
myoma, hysterectomies performed for other clinical conditions
such as endometriosis, uterine prolapse, and cancer may also lead
to diagnosis of leiomyoma. We assessed whether the leiomyoma
signals are driven by endometriosis cases within the leiomyoma
group. To this end, we removed all known endometriosis cases
from the Icelandic leiomyoma sample set and compared the
association results with the results obtained for the full Icelandic
leiomyoma group. The effects of leiomyoma associations were not
diminished for any of the variants (Supplementary Data 6). We
note that since we only have information on surgically diagnosed
endometriosis cases, it is possible that there may be some
undiagnosed cases left in the leiomyoma group. We also assessed
the association of all 19 reported endometriosis variants32 with
the endometriosis-excluded leiomyoma group. Only rs12037376
(CDC42/WNT4), rs71575922 (SYNE1/ESR1), and rs77294520
(GREB1) associate with leiomyoma after correction for the
number of tests (P < 0.05/19= 2.6 × 10−3), with all three variants
showing the same direction of effect for endometriosis and leio-
myoma (logistic regression, Supplementary Data 7).
We tested if the leiomyoma variants associate with endometrial
cancer, using 2462 endometrial cancer cases (1009 from Iceland
and 1453 from UKB) and 336,978 controls (218,565 from Iceland
and 118,413 from UKB) (Supplementary Data 9). Only
rs10917151 (CDC42/WNT4) associates with endometrial cancer
(P= 4.5 × 10−4, logistic regression, OR 1.14) after correcting for
the number of tests (P= 0.05/21= 0.0024). We also tested the
association between leiomyoma and seven variants reported in
GWAS studies of endometrial cancer41. None of the endometrial
cancer variants associate with leiomyoma (Supplementary
Data 10).
Functional annotation of non-coding leiomyoma variants. To
assess the functional role of the non-coding leiomyoma variants,
we annotated the lead non-coding variants along with correlated
variants (r2 > 0.8, N= 438), using data on regulatory regions in
uterine tissue from the Encode project (www.encodeproject.org).
Speciﬁcally, we focused on acetylation of lysine K27 of histone H3
(H3K27ac) and open chromatin regions (DNase Hypersensitivity
Sites; DHS). This analysis identiﬁed 51 out of 438 variants
that intersected with H3K27ac marked regions (Supplementary
Data 11). In addition, 14 variants were found within DHS sites, of
which 10 are also within H3K27ac regions. To search for gene
targets of variants in regulatory regions, we analyzed chromatin
interaction maps and identiﬁed 85 potential target genes that
associate with one or more of the candidate regulatory variants
(Supplementary Data 11, Fig. 2, Supplementary Fig. 2). Genes
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whose transcription start sites (TSS) are found within 1 kb of a
regulatory variant are listed (Supplementary Data 11).
The variant rs58415480 at 6q25.2 (SYN1/ESR1) is in strong LD
with only one other variant, rs71575922 (r2= 0.96) and both
reside in a regulatory region in the uterine tissue. According to
chromosomal interaction data, rs58415480 and rs71575922 are
candidate regulators of seven target genes including ESR1, which
is important in the growth of leiomyomas (Fig. 2, upper panel).
The variant on chromosome 13, rs117245733, does not have a
strongly correlated marker. This variant resides in a region
densely marked by H3K27ac in the uterine tissue, indicative of
regulatory activity (Fig. 2, lower panel). Out of the eleven
candidate target genes regulated by rs117245733, the FOXO1 gene
is notable, as its expression in primary human endometrial
stromal cells is regulated by ESR142 and it is a direct
protein–protein interaction partner of ESR1 in breast cancer
cells43. The secondary signal at 13q14.11, rs7986407, also targets
FOXO1 (Supplementary Fig. 2). At 11p13, the well-known tumor
suppressor gene WT1 interacts with several variants, with
rs10835884, rs11031716, and rs11828433 representing the top-
ranking causal variants (Supplementary Data 11, Supplementary
Fig. 2). According to the Human Protein Atlas (www.proteinatlas.
org), WT1 expression is limited to smooth muscle cells of the
uterus, in addition to Fallopian tube, testis, and kidney tissue.
Heritability and polygenic score (PGS). We used LD score
regression44 to estimate the SNP heritability of leiomyoma. Using
the Icelandic population, we estimate the SNP heritability to be
13% (95% CI 4–22%). We estimate the sibling recurrence risk in
Iceland to be 1.74 (95% CI 1.63, 1.85, P < 0.0001) and ﬁnd that
the proportion of sibling recurrence risk for leiomyoma explained
by the 21 variants is 10.8%.
< ZBTB2
H3K27ac
DHS
rs71575922 rs58415480
CCDC170 >
ESR1 >
SYNE1–AS1 >
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MYCT1 >
< SYNE1
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Fig. 2 Leiomyoma risk variants intersecting with regulatory regions and their candidate target genes. Two loci on chromosomes 6 (upper panel) and 13
(lower panel) are shown as examples. Acetylation of lysine residue K27 of histone H3 (H3K27ac) and open chromatin (DHS, DNase Hypersensitivity Sites)
in the uterus samples are shown as tick marks at the top. At chromosome 6, the lead variant rs58415480 is shown along with the only other variant in the
same LD class (r2 > 0.8), rs71575922. At chromosome 13, rs117245733 is in an LD class by itself, i.e., does not have strongly correlated markers. Candidate
target genes were identiﬁed by the analysis of available chromatin interaction maps, shown on the ﬁgure as orange arcs. The shaded regions represent
regions found in contact with the regulatory variants
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The sharing of susceptibility loci of leiomyoma with different
tumor types on one hand and hormone-related traits on the other
suggests that leiomyomas are genetically correlated with these
phenotype groups. We used a polygenic score (PGS) to map the
genetic correlation between leiomyoma and 28 selected tumor/
hormone-related phenotypes (Table 2). To avoid confounding,
risk alleles, P-values, and effect estimates were extracted from the
UKB study on leiomyoma and used to calculate a standardized
PGS for the genotyped cases in the Icelandic dataset. As expected,
the PGS associates with leiomyoma in the Icelandic dataset
(OR= 1.25, P= 3.2 × 10−55), which may be interpreted such that
one standard deviation increase in the PGS leads to a 25%
increased chance of leiomyoma. After correction for the number
of phenotypes tested (P < 0.05/29= 1.72 × 10−3), the PGS was
also signiﬁcantly correlated with the risk of being diagnosed with
cancer (all cancer types together), thyroid cancer and prostate
cancer (likelihood ratio test, Table 2).
Discussion
Results from this meta-analysis highlight two distinct genetic
pathways that play a role in the development of leiomyomas; one
of genes linked to tumorigenesis (TP53, TERT, ATM, and
OBFC1) and the other of variants and loci linked to hormone
metabolism (CDC42/WNT4, GREB1, MCM8, and SYN1/ESR1). It
is tempting to speculate that the tumor-associated variants pro-
vide genetic background for leiomyoma development, whereas
the hormone-associated variants enhance the growth of the
tumors, causing them to become symptomatic. A common
genetic etiology between cancer and leiomyoma is further sug-
gested by the leiomyoma PGS that associates with several cancers,
including a phenotype consisting of individuals affected by any
type of cancer. We did not have the power to test the association
of the variants with leiomyosarcoma—the malignant tumor ori-
ginating in the myometrium— because of the rarity of this tumor
type (44 cases in this study).
The association between leiomyoma and the 3′UTR variant in
TP53 is of particular interest. Contrary to most pathogenic
mutations in TP53, the variant does not change the amino acid
sequence of the protein, but instead disrupts normal poly-
adenylation and reduces the abundance of mRNA11. This results
in a cancer risk spectrum quite distinct from the Li–Fraumeni
tumor syndrome. Notably, the variant predisposes to some non-
lethal tumor types such as basal cell skin cancer and colorectal
adenomas, but not colorectal cancer11. The association between
missense variants in ATM and leiomyoma is also unexpected. We
have previously shown that loss-of-function mutations in ATM
confer high risk of gastric cancer in the Icelandic population45.
These same loss-of-function variants do not associate with leio-
myoma risk, suggesting that the missense variants may have a
mild effect on some speciﬁc functions of ATM in uterine tissue.
Here, we report for the ﬁrst time an association between the
missense variant Asp1853Asn in ATM (rs1801516) and increased
risk of squamous cell skin cancer.
In conclusion, we report the ﬁrst GWAS of leiomyoma in
European populations. Our results show a genetic overlap
between leiomyoma and various cancers, and highlight the role
of estrogen in tumor growth.
Methods
Datasets. The meta-analysis combined the results of two GWAS of uterine leio-
myoma. The Icelandic dataset consisted of 6,728 histologically conﬁrmed cases of
leiomyoma of the uterus (ICD codes ICD10 D25 and ICD9 218 and 219) diagnosed
at the Department of Pathology, Landspitali University Hospital, compared to
Table 2 Polygenic risk score analysis using chip-genotyped cases and controls in Iceland
Case-control phenotypes N aff N ctrl R2 [%] P OR (95% CI)
Leiomyoma of Uterus 5234 123,894 0.60% 3.2E-55 1.25 (1.22 1.29)
Leiomyoma wo endometriosis 4876 124,252 0.58% 1.4E-50 1.25 (1.21 1.29)
All Cancer 19,712 124,522 0.02% 2.8E-06 1.04 (1.02 1.06)
Thyroid Cancer 696 136,207 0.21% 3.0E-05 1.17 (1.09 1.26)
Prostate Cancer 3434 100,757 0.03% 1.7E-03 1.06 (1.02 1.1)
Kidney Cancer 734 112,893 0.10% 2.4E-03 1.12 (1.04 1.2)
Endometriosis 1385 134,434 0.05% 3.4E-03 1.08 (1.02 1.14)
Endometriosis Stage III and IV 542 127,502 0.11% 4.1E-03 1.13 (1.04 1.23)
Colorectal adenoma 8735 128,569 0.01% 7.5E-03 1.03 (1.01 1.05)
MGUS 978 121,348 0.04% 0.022 1.08 (1.01 1.15)
BCC 3948 125,581 0.01% 0.036 1.04 (1.01 1.07)
Cervical Cancer 377 136,526 0.07% 0.049 1.11 (1 1.23)
Melanoma 1281 141,744 0.01% 0.16 1.04 (0.98 1.1)
Bladder Cancer 1106 136,208 0.01% 0.20 0.961 (0.9 1.02)
Breast Cancer 3685 140,325 0.00% 0.27 1.02 (0.99 1.06)
UADT Cancer 268 113,299 0.02% 0.32 0.941 (0.83 1.06)
Leiomyosarcoma 22 96,914 0.26% 0.36 1.22 (0.8 1.85)
SQCSC 1452 135,852 0.00% 0.43 0.979 (0.93 1.03)
Gastric Cancer 411 93,609 0.00% 0.58 1.03 (0.93 1.14)
NH Lymphoma 558 142,467 0.00% 0.66 1.02 (0.94 1.11)
Brain Cancer 172 142,343 0.01% 0.69 1.03 (0.89 1.2)
Pancreatic Cancer 324 103,797 0.00% 0.74 0.981 (0.88 1.1)
Ovarian Cancer 280 141,320 0.00% 0.88 1.01 (0.9 1.14)
Endometrial Cancer 564 121,762 0.00% 0.94 0.997 (0.92 1.08)
Lung Cancer 1972 120,354 0.00% 0.95 0.998 (0.95 1.04)
Colorectal Cancer 2001 127,528 0.00% 0.95 0.998 (0.95 1.04)
Quanititative trait phenotypes N aff N ctrl R2 P Beta
Age at Menopause 9719 NA 1.00E−04 0.20 0.049 (−0.03 0.12)
BMD Spine 22,059 NA 0.00% 0.38 0.006 (−0.01 0.02)
BMD Hip 24,297 NA 0.00% 0.86 0.001 (−0.01 0.01)
R2 denotes explained variance, OR is the odds ratio for binary phenotypes, and Beta is the effect for qtl phenotypes
MGUS monoclonal gammopathy of undetermined signiﬁcance, BCC basal cell carcinoma of the skin, UADT upper aero-digestive tract, SQCSC squamous cell skin cancer, BMD bone mineral density
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124,542 female controls. The UK Biobank (UKB) leiomyoma dataset consisted of
9,867 cases with ICD10 D25 compared to 398,788 controls of both sexes. The UKB
phenotype is based on diagnoses codes recorded for a participant during all visits to
a hospital. Given the high prevalence of leiomyoma, it is clear that a fraction of the
controls in both datasets will have undiagnosed leiomyoma. This under-diagnosis
of the controls weakens the power of the GWAS, but should not lead to false-
positive results.
The Icelandic cancer case–control datasets used were described previously46.
The primary source of information on cancer is the Icelandic Cancer Registry
(ICR), which has registered all solid, non-cutaneous cancers in the entire
population of Iceland since 195547. Registration of skin and hematological cancers
started in 1980s. ICR registration is based on the ICD system and includes
information on histology (systemized nomenclature of medicine, SNOMED). Over
94% of diagnoses in the ICR have histological conﬁrmation. The endometriosis32,
bone phenotype48, and age at menopause49 datasets have been described
previously. For sex-speciﬁc phenotypes in Iceland, only controls for the relevant sex
were included in the analysis.
The study was approved by the Icelandic National Bioethics Committee
(reference number. 17–124). Written informed consent was obtained from all
genotyped subjects.
Genotyping. The Icelandic part of the study is based on the genotypes of 150,656
Icelanders, who have been genotyped using Illumina SNP chips along with whole-
genome sequence (WGS) data from 15,220 Icelanders. The genotypes for the
150,656 individuals were long-range phased and imputed using information from
the WGS individuals50. Using genealogic information, the sequence variants were
imputed into 282,894 relatives of the genotyped individuals to further increase the
sample size for association analysis and to increase the power to detect the asso-
ciations51. A total of 34.5 million variants were used in the Icelandic GWAS.
Datasets were constructed as a part of disease association efforts at deCODE
genetics. For further information regarding genotyping and imputation, we refer to
Gudbjartsson et al.52
Genotyping of UKB samples was performed using a custom-made Affymetrix
chip, UK BiLEVE Axiom53, and with the Affymetrix UK Biobank Axiom array54.
Imputation was performed by the Wellcome Trust Centre for Human Genetics,
using the Haplotype Reference Consortium (HRC) and the UK10K haplotype
resources55. This yields a total of 96 million imputed variants, however only 27
million variants imputed using the HRC reference set passed the quality ﬁlters used
in our study.
GWAS and meta-analysis. Logistic regression assuming an additive model was
used to test for association between variants and disease, treating disease status as
the response and expected genotype counts from imputation as covariates, and
using the likelihood ratio test to compute P-values. The association analysis for
both the Icelandic and UKB datasets was done using a software developed at
deCODE genetics52. For the Icelandic study group, patients and controls are
matched on gender and age at diagnosis or age at inclusion, and information on
county of origin within Iceland are included as covariates to adjust for possible
population stratiﬁcation. For the UK datasets, cases and controls are restricted to
individuals of genetically conﬁrmed white British origin, and 40 principle com-
ponents are included in the analysis to adjust for population substructure. To
account for inﬂation in test statistics due to cryptic relatedness and stratiﬁcation,
we applied the method of linkage disequilibrium (LD) score regression44 to esti-
mate the inﬂation in test statistics and adjusted all P values accordingly. The
estimated correction factor for Leiomyoma based on LD score regression was 1.13
for the Icelandic and 1.10 for the UK datasets, respectively.
Variants in the UKB imputation dataset were mapped to NCBI Build38
positions and matched to the variants in the Icelandic dataset based on allele
variation. The results from the two cohorts were combined using a ﬁxed-effect
model, in which the cohorts were allowed to have different population frequencies
for alleles and genotypes, but were assumed to have a common OR and were
weighted with the inverse of the variance. We selected a threshold of 0.9
imputation info for variants available in the Icelandic dataset and 0.8 imputation
info for variants only available in the UKB dataset. A total of 43,421,991 variants
were used in the analysis. Heterogeneity was tested by comparing the null
hypothesis of the effect being the same in all populations to the alternative
hypothesis of each population having a different effect using a likelihood ratio test.
We used the weighted Holm–Bonferroni method56 to account for all 43,421,991
variants being tested (P-value < (0.05×weight)/43,421,991). Using the weighing
scheme given in Sveinbjornsson et al.10, this procedure controls the family-wise
error rate at 0.05; P ≤ 2.1 × 10−7 for high-impact variants (including stop-gained
and loss, frameshift, splice acceptor or donor and initiator codon variants, n=
13,264), P ≤ 5.0 × 10−8 for missense, splice-region variants and in-frame-indels
(n= 257,401), P ≤ 4.6 × 10−9 for low-impact variants (including synonymous,
3′ and 5′ UTR, and upstream and downstream variants, n= 3,303,568), P ≤ 2.0 ×
10−9 for deep intronic and intergenic variants in DNase I hypersensitivity sites
(DHS) (n= 5,999,736), and P ≤ 7.6 × 10−10 for other non-DHS deep intronic and
intergenic variants (n= 33,998,502).
Conditional analysis. We applied approximate conditional analyses, implemented
in the GCTA software57, to the meta-analysis summary statistics to look for
additional association signals at each of the genome-wide signiﬁcant loci. LD
between variants was estimated using a set of 8700 whole-genome sequenced
Icelandic individuals. The analysis was restricted to variants present in both the
Icelandic and UKB datasets and within 1Mb from the index variants. We tested 16
loci and about 30,000 variants in the conditional analysis and reported variants
with conditional P value < 10−6. The results from GCTA were veriﬁed by condi-
tional analysis using genotype data in the Icelandic and UK datasets separately, and
the results presented in Table 1 are obtained by meta-analyzing those results.
Polygenic score, heritability, and explained variance. We derived a leiomyoma
polygenic risk score (PGS) for the Icelandic individuals and, to avoid bias, we only
used effect estimates from the GWAS summary results for leiomyoma from the UK
dataset. The PGS was calculated using genotypes for about 630,000 autosomal
markers included on the Illumina SNP chips to avoid uncertainty due to impu-
tation quality. We estimated linkage disequilibrium (LD) between markers using
14,938 phased Icelandic samples and used this LD informaton to calculate adjusted
effect estimates using LDpred58,59. We created several PGSs assuming different
fractions of causal markers (the P parameter in Ldpred) and selected the best one
based on the prediction of leiomyoma in the Icelandic dataset (0.3% causal var-
iants). This PGS was then used when we calculate the correlation of the PGS with
other phenotypes in the Icelandic dataset.
We computed LD scores for genotyped individuals in the Icelandic cohort using
only high-quality markers and estimated the heritability explained by all markers,
with MAF above 1% using LD score regression44. We estimated the risk ratio
among siblings (λS) of Icelandic leiomyoma cases (N= 6728) by cross-matching
with a genealogy database that covers the entire Icelandic nation. The risk ratio
among siblings (λS) was estimated at 1.74 [1.63, 1.85] (P < 0.0001) using an
approach previously described by Edvardsson et al60. This allows us to calculate the
proportion of sibling recurrence risk of leiomyoma explained by the signals
identiﬁed in the present study, log(λS[i])/log(λS)61.
Functional annotation of leiomyoma variants. Variants in linkage disequilibrium
(LD) with the lead variants were identiﬁed on the basis of in-house genotype data
using r2 > 0.8 for pairwise comparison of the nearest 100,000 variants to deﬁne an
LD class. These variants were then annotated by intersection with chromatin
immunoprecipitation (ChIP) signal data for uterine tissue. The ChIP-seq data was
derived from the ENCODE project (www.encodeproject.org) downloaded in pre-
processed (MACS v2 algorithm) bigWig format representing analysis of acetylation
of lysine K27 of histone H3 (H3K27ac) with accession number ENCFF407ITR. The
signal P-values were adjusted by the Benjamini-Hochberg procedure to account for
multiple hypothesis and thresholded at the 1% FDR signiﬁcance level. DNase
hypersensitivity data (DHS) for uterus tissue were also downloaded in pre-
processed format, accession number ENCFF604WBU, and intersected with variant
position in each LD class.
Chromatin interaction map data were derived from Hi-C sequencing for
various cell types and primary tissue samples62. The data were downloaded from
Omnibus, accession number GSE87112, in pre-processed format (Fit-Hi-C
algorithm) representing false-discovery rates (FDR) for contact regions at 40 kb
resolution. To deﬁne statistically signiﬁcant contacts we used a threshold value of
FDR < 10−6 in mesoendoderm cells62. We conﬁned this analysis to variants
residing within candidate regulatory regions based on Encode data for H3K27ac
and DHS in uterus tissue. The regions found to interact with the variant-containing
regions were then queried for Refseq genes and intersected with a database for
cancer genes (NCG 5.0; ncg.kcl.ac.uk) and tissue-speciﬁc expression patterns as
provided in the Human Protein Atlas (www.proteinatlas.org), v18 downloaded in
December 2017.
Data availability
The Icelandic population WGS data has been deposited at the European Variant Archive
under accession code PRJEB8636. The authors declare that the data supporting the
ﬁndings of this study are available within the article, its Supplementary Data ﬁles and
upon request. The UK Biobank data can be obtained upon application (ukbiobank.ac.uk).
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